A Guide for the Perplexed

Slides:



Advertisements
Similar presentations
HEART FAILURE (HF) Heart failure is the pathophysiological state in which an abnormality of cardiac function is responsible for failure of the heart to.
Advertisements

Calcium Homeostasis and Signaling in Yeast Cells and Cardiac Myocytes Jiangiun Cui, J.A. Kaandorp, P.M.A. Sloot Section Computational Science University.
Muscles and Muscle Tissue: Smooth Muscle Part C2 Prepared by Janice Meeking, W. Rose, and Jarvis Smith. Figures from Marieb & Hoehn 8 th ed. Portions copyright.
objectives Overview of the cardiovascular system Cardiac muscle and the heart The heart as a pump Excitation-contraction coupling and relaxation in cardiac.
GROUP 4.
Human Anatomy & Physiology FIFTH EDITION Elaine N. Marieb PowerPoint ® Lecture Slide Presentation by Vince Austin Copyright © 2003 Pearson Education, Inc.
INTRACELLULAR CALCIUM RELEASE IN NORMAL AND DISEASED HEART Sandor Gyorke DHLRI, 507.
Cardiac Muscle II. Excitation-contraction coupling in the heart.
Frank-Starling Mechanism
Cardiac Output. Which Hearts Are Healthy? Stroke Volume? End-systolic volume Stroke volume Left Ventricle Volume (ml) End-diastolic volume.
Copyright © 2006 Pearson Education, Inc., publishing as Benjamin Cummings Electrocardiography  Electrical activity is recorded by electrocardiogram (ECG)
Mechanisms of Myocardial Contraction Dr. B. Tuana.
Copyright © 2006 Pearson Education, Inc., publishing as Benjamin Cummings Differences in Contraction Mechanisms  Heart has autorhythmicity (approx. 1%)
Coronary Heart Disease. Coronary Circulation Left Coronary Artery –Anterior descending –Circumflex Right Coronary Artery –Posterior descending Veins –Small,
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Contractile Function During Angiotensin-II Activation:
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cirrhotic Cardiomyopathy J Am Coll Cardiol. 2010;56(7):
MODULATABLE (STIMULATION) FUNCTION SECONDARY DAMAGE SUPPORT ACTIVATION OF COMPENSATORY MECHANISMS* ● Adrenergic ● RAAS ● Other INTRINSIC (RESTING) FUNCTION.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Sympathetic Nervous System in Heart Failure:
Donna H. Korzick, Ph.D. Noll Physiological Research Center and The Department of Kinesiology Regulation of Cardiac EC-Coupling: A Cellular Update Experimental.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Scavenging Free Radicals by Low-Dose Carvedilol.
VASOACTIVE DRUGS February 2017
Pharmacotherapy Of Cardiovascular Disorders: Heart Failure
Cardiac excitation-contraction coupling and its regulation by positive inotropic drugs. The cardiac cycle is initiated by membrane depolarization, which.
The Ca2+ fluxes and key structures involved in cardiac excitation-contraction coupling. The arrows denote the direction of Ca2+ fluxes. The thickness of.
HEART FAILURE ACUTE (cardiogenic shock) CHRONIC (congestive)
Left Ventricular Dysfunction With Pulmonary Hypertension
Does a Vitamin D Boost Help in Resistant Hypertension Control?
Cyclic nucleotide signalling in cardiac myocytes and its relation to contraction and arrhythmias. Cyclic nucleotide signalling in cardiac myocytes and.
Voltage-gated ion channels
Potassium Channels and Proliferation of Vascular Smooth Muscle Cells
Section III: Neurohormonal strategies in heart failure
The pathophysiology of myocardial infarction-induced heart failure
Translation initiation factor eIF2: Initiation and Recycling
Important pathophysiologic mechanisms in HF (1)
Ch 13: Heart concepts:.
C.Allyson Walker, BA, Francis G. Spinale, MD, PhD 
HFpEF, a Disease of the Vasculature: A Closer Look at the Other Half
Cirrhotic cardiomyopathy
Nat. Rev. Cardiol. doi: /nrcardio
Getting Pumped about Heart Failure
Stress Pathways and Heart Failure
Diastolic heart failure in anaesthesia and critical care
Xander H.T. Wehrens, MD, PhD, Andrew R. Marks, MD 
Step Care Therapy for Hypertension in Diabetic Patients
Calcium Signaling and the Control of Dendritic Development
Eugene Braunwald JCHF 2013;1:1-20
K May 03 03/05/23 1.
C. Allyson Walker, BA, Fred A. Crawford, MD, Francis G
Chapter 21: Drugs for Hypertension
Nat. Rev. Cardiol. doi: /nrcardio
Michael G. Katz, MD, PhD, Anthony S. Fargnoli, PhD, Andrew P
K May 03 03/05/21 1.
Altered Myocardial Calcium Cycling and Energetics in Heart Failure—A Rational Approach for Disease Treatment  Przemek A. Gorski, Delaine K. Ceholski,
Anti hypertensive Drugs
Chapter 14 Blood Pressure – Regulation and Pathology
Volume 101, Issue 4, Pages (May 2000)
Intracellular Ca2+ Release and Ischemic Axon Injury
Hypertension, Na+/Ca2+ exchanger, and Na+, K+-ATPase
Heme oxygenase: protective enzyme or portal hypertensive molecule?
Chapter 17: Function of the Heart
Eugene Braunwald JCHF 2013;1:1-20
Endothelial regulation: Understanding RAS
William C. Stanley, Fabio A. Recchia  Cell Metabolism 
Nat. Rev. Cardiol. doi: /nrcardio
Impaired Lung Function and Risk for Stroke
Linking Calcium to Aβ and Alzheimer's Disease
β-Blocker Use for the Stages of Heart Failure
One Small Step for Muscle: A New Micropeptide Regulates Performance
Model of regulatory pathways for the mineralocorticoid receptor (MR) in intercalated cells: hyperkalemia and volume depletion. Model of regulatory pathways.
Fig. 2. Potential mechanisms and effects of impaired Ca2+ handling in DC. Impairment in cardiomyocyte Ca2+ influx and efflux, impaired release and reuptake.
Presentation transcript:

A Guide for the Perplexed by Andrew R. Marks Circulation Volume 107(11):1456-1459 March 25, 2003 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. Regulation of key molecules in cardiac EC coupling by stress activated pathways. Figure 1. Regulation of key molecules in cardiac EC coupling by stress activated pathways. The normal fight or flight stress response activates 3 key molecules involved in cardiac EC coupling via PKA phosphorylation: (1) the trigger for cardiac EC coupling, the voltage-gated Ca2+ channel (VGCC); (2) the SR Ca2+ release channel RyR2; and (3) the Ca2+ uptake pathway (via PKA phosphorylation of phospholamban which reduces inhibition of the Ca2+-ATPase SERCA2a). These regulatory events conspire to increase systolic SR Ca2+ release and thereby increase contractility, providing increased cardiac output to meet metabolic demands of stressful conditions. In failing hearts, this system becomes defective because of the maladaptive chronic hyperadrenergic state of heart failure, resulting in PKA-hyperphosphorylated RyR2 channels that cause a diastolic SR Ca2+ leak1 that conspires with reduced SERCA2a-mediated SR Ca2+ uptake (due in part to PKA hypophosphorylated phospholamban which inhibits SERCA2a) to deplete SR Ca2+ and contribute to contractile dysfunction of cardiac muscle. Andrew R. Marks Circulation. 2003;107:1456-1459 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. A molecular model of heart failure. Figure 2. A molecular model of heart failure. The maladaptive response to cardiac muscle damage from myocardial infarction (MI), viral infection, or pressure overload due to hypertension (HTN) or valve disease results in activation of signaling pathways including adrenergic, renin angiotensin (RAS), and cytokine, designed as stress responses. The chronic activation of these pathways in heart failure results in defects in EC coupling including: (1) PKA hyperphosphorylation of the cardiac ryanodine receptor (RyR2) that results in depletion of FKBP12.6 (which helps keep the channel closed in diastole) from the channel macromolecular complex, causing a diastolic Ca2+ leak that depletes sarcoplasmic reticulum (SR) Ca2+; and (2) reduced SR Ca2+ reuptake via SERCA2a.14 Other defects in the maladaptive response in heart failure include alterations in the cytoskeleton15,16 and the extracellular matrix (imbalance between matrix metalloproteinases [MMPs] and tissue inhibitors of metalloproteinases [TIMPs]).17 Andrew R. Marks Circulation. 2003;107:1456-1459 Copyright © American Heart Association, Inc. All rights reserved.